Can Nexium and Capecitabine Be Taken Together?
Yes, Nexium (esomeprazole) can be taken together with capecitabine, as there is no pharmacokinetic interaction that reduces capecitabine efficacy, despite earlier concerns about PPI-induced pH changes affecting absorption.
Key Evidence from Drug Labeling
The FDA-approved Nexium prescribing information does not list capecitabine as a contraindicated or cautionary drug interaction 111. The drug label specifically addresses interactions with drugs dependent on gastric pH for absorption (such as erlotinib, dasatinib, and ketoconazole) but capecitabine is notably absent from this list, indicating no recognized clinically significant interaction.
Definitive Pharmacokinetic Study
The most recent and highest-quality prospective evidence directly addresses this question: A 2022 randomized crossover trial specifically examined esomeprazole's effect on capecitabine pharmacokinetics 2. This study found:
- Capecitabine exposure (AUC) increased by 18.9% with esomeprazole (not decreased as previously hypothesized)
- The half-life of capecitabine was significantly longer with esomeprazole (0.63 vs 0.46 hours, p=0.005)
- No negative impact on capecitabine bioavailability occurred
This prospective data directly contradicts the theoretical concern that PPIs would impair capecitabine absorption through pH-mediated effects.
Addressing Conflicting Retrospective Data
Earlier retrospective analyses suggested worse outcomes with PPI use:
- A 2017 secondary analysis of the TRIO-013 trial reported poorer progression-free survival (4.2 vs 5.7 months) and overall survival (9.2 vs 11.3 months) in PPI-treated patients receiving capecitabine 3
- However, these were retrospective observational findings subject to confounding by indication (sicker patients may require PPIs for other reasons)
The 2022 prospective pharmacokinetic study 2 specifically concluded that "altered capecitabine pharmacokinetics do not explain the assumed worse clinical outcome of PPI-cotreated patients," suggesting any observed clinical differences are not due to drug-drug interaction but rather patient-related factors.
Clinical Recommendation
- Continue both medications together if clinically indicated for their respective conditions
- No dose adjustments of capecitabine are required when co-administered with esomeprazole
- The theoretical pH-based interaction does not manifest as clinically relevant pharmacokinetic changes
- If retrospective survival differences exist, they likely reflect patient comorbidities rather than true drug interaction
Important Caveat
While capecitabine and esomeprazole can be safely co-administered, monitor for capecitabine's standard toxicities (hand-foot syndrome, diarrhea, myelosuppression) as you would in any patient, regardless of PPI use.